JP2006504761A5 - - Google Patents

Download PDF

Info

Publication number
JP2006504761A5
JP2006504761A5 JP2004547576A JP2004547576A JP2006504761A5 JP 2006504761 A5 JP2006504761 A5 JP 2006504761A5 JP 2004547576 A JP2004547576 A JP 2004547576A JP 2004547576 A JP2004547576 A JP 2004547576A JP 2006504761 A5 JP2006504761 A5 JP 2006504761A5
Authority
JP
Japan
Prior art keywords
chloro
alkyl
phenyl
acetamide
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004547576A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006504761A (ja
Filing date
Publication date
Priority claimed from DE10250743A external-priority patent/DE10250743A1/de
Application filed filed Critical
Publication of JP2006504761A publication Critical patent/JP2006504761A/ja
Publication of JP2006504761A5 publication Critical patent/JP2006504761A5/ja
Pending legal-status Critical Current

Links

JP2004547576A 2002-10-31 2003-10-28 Mch拮抗活性を有する新規アミド化合物及びこれらの化合物を含む薬物 Pending JP2006504761A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10250743A DE10250743A1 (de) 2002-10-31 2002-10-31 Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
PCT/EP2003/011933 WO2004039764A1 (de) 2002-10-31 2003-10-28 Neue amid-verbindungen mit mch-antagonistischer wirkung und diese verbindungen enthaltende arzneimittel

Publications (2)

Publication Number Publication Date
JP2006504761A JP2006504761A (ja) 2006-02-09
JP2006504761A5 true JP2006504761A5 (https=) 2009-10-08

Family

ID=32115015

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004547576A Pending JP2006504761A (ja) 2002-10-31 2003-10-28 Mch拮抗活性を有する新規アミド化合物及びこれらの化合物を含む薬物

Country Status (24)

Country Link
EP (1) EP1558567B1 (https=)
JP (1) JP2006504761A (https=)
KR (1) KR20050065654A (https=)
CN (1) CN1708476A (https=)
AR (1) AR041735A1 (https=)
AT (1) ATE434601T1 (https=)
AU (1) AU2003285306A1 (https=)
BR (1) BR0315797A (https=)
CA (1) CA2504207C (https=)
CO (1) CO5570698A2 (https=)
DE (2) DE10250743A1 (https=)
EA (1) EA009040B1 (https=)
EC (1) ECSP055765A (https=)
ES (1) ES2327329T3 (https=)
HR (1) HRP20050383A2 (https=)
MX (1) MXPA05002865A (https=)
NO (1) NO20050745L (https=)
PE (1) PE20040785A1 (https=)
PL (1) PL376256A1 (https=)
RS (1) RS20050330A (https=)
TW (1) TW200412936A (https=)
UY (1) UY28051A1 (https=)
WO (1) WO2004039764A1 (https=)
ZA (1) ZA200501164B (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
FR2866880A1 (fr) * 2004-02-27 2005-09-02 Oreal Para-phenylenediamine secondaire n-alkylaminee ortho-et/ou meta-substituee, composition de teinture des fibres keratiniques contenant une telle para-phenylenediamine, procedes mettant en oeuvre cette composition et utilisations
US7605176B2 (en) 2004-03-06 2009-10-20 Boehringer Ingelheim International Gmbh β-ketoamide compounds with MCH antagonistic activity
JP2006076990A (ja) * 2004-03-12 2006-03-23 Bayer Cropscience Ag 殺虫性ベンゼンジカルボキサミド類
DE102004017934A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7524862B2 (en) 2004-04-14 2009-04-28 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
KR20090047542A (ko) 2006-08-25 2009-05-12 베링거 인겔하임 인터내셔날 게엠베하 Mch 길항 활성을 갖는 신규한 피리돈 유도체 및 당해 화합물을 포함하는 의약
WO2008069611A1 (en) * 2006-12-08 2008-06-12 Korea Research Institute Of Chemical Technology N-phenylamide derivative, process for the preparation thereof, and composition for preventing or treating ischemic diseases comprising same
TW200831485A (en) 2006-12-11 2008-08-01 Boehringer Ingelheim Int New pyridazine derivatives with MCH antagonistic activity and medicaments comprising these compounds
WO2010015680A1 (en) * 2008-08-07 2010-02-11 Bayer Cropscience Sa Fungicide oxyalkylamide derivatives
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5557845B2 (ja) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9079880B2 (en) * 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
WO2012008549A1 (ja) * 2010-07-15 2012-01-19 武田薬品工業株式会社 複素環化合物
BR112013021236B1 (pt) 2011-02-25 2021-05-25 Merck Sharp & Dohme Corp composto derivado de benzimidazol, e, composição
SMT201800171T1 (it) 2011-07-29 2018-07-17 Karyopharm Therapeutics Inc Modulatori di trasporto nucleare contenenti idrazide e loro usi
US9428490B2 (en) * 2011-07-29 2016-08-30 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2013148333A1 (en) 2012-03-28 2013-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Salicylic acid derivatives useful as glucocerebrosidase activators
CA2872190C (en) 2012-05-09 2024-06-25 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
US10202366B2 (en) 2013-03-15 2019-02-12 Karyopharm Therapeutics Inc. Methods of promoting wound healing using CRM1 inhibitors
DK3492455T3 (da) 2013-06-21 2023-08-14 Karyopharm Therapeutics Inc 1,2,4-triazoler som nukleare transportmodulatorer og anvendelse til behandling af specifikke former for cancer
WO2014209034A1 (en) 2013-06-27 2014-12-31 Lg Life Sciences Ltd. Biaryl derivatives as gpr120 agonists
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN111484483B (zh) 2014-08-15 2023-05-26 卡尔约药物治疗公司 赛灵克斯的多晶型物
CN105439914B (zh) * 2014-09-17 2017-07-11 复旦大学 4‑氨酰基苯氧乙酰胺类化合物及其药物用途
AU2015367977B9 (en) 2014-12-24 2020-02-06 Lg Chem, Ltd Biaryl derivative as GPR120 agonist
JP6533997B2 (ja) * 2014-12-26 2019-06-26 株式会社ヤクルト本社 Znf143阻害活性を有する化合物およびその利用
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2017117535A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2017157873A1 (en) 2016-03-17 2017-09-21 F. Hoffmann-La Roche Ag 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
KR20220034818A (ko) 2019-07-10 2022-03-18 바이엘 악티엔게젤샤프트 2-(페닐이미노)-1,3-티아졸리딘-4-온의 제조 방법
CN117177744A (zh) 2021-01-29 2023-12-05 塞迪拉治疗股份有限公司 Cdk2抑制剂及其使用方法
MX2023015436A (es) 2021-06-26 2024-02-21 Cedilla Therapeutics Inc Inhibidores de cdk2 y metodos de uso de los mismos.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2338804A1 (en) * 1998-07-28 2000-02-10 Smithkline Beecham Corporation Propenamides as ccr5 modulators
EP1218336A2 (en) * 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
EP1299362A4 (en) * 2000-07-05 2004-11-03 Synaptic Pharma Corp SELECTIVE RECEPTOR ANTAGONISTS OF MELANINE CONCENTRATING HORMON-1 (MCH1) AND THEIR USE
US20030022891A1 (en) * 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
WO2003035055A1 (en) * 2001-10-25 2003-05-01 Schering Corporation Mch antagonists for the treatment of obesity

Similar Documents

Publication Publication Date Title
JP2006504761A5 (https=)
RU2201927C2 (ru) Амидиновые соединения и фармацевтическая композиция, обладающая фактор ха ингибирующим действием
CA2504207A1 (en) New amide compounds having mch-antagonistic activity and medicaments comprising these compounds
US6939891B2 (en) Heterocyclic ureas, their preparation and their use as vanilloid receptor antagonists
JP2007528883A5 (https=)
BG64848B1 (bg) Циклични аминопроизводни и използването им като лекарства
JP2004508304A5 (https=)
RU2003136097A (ru) Производные фенилпиридинкарбонилпиперазина
JP2005513123A5 (https=)
WO2006112685A1 (en) Neurotherapeutic azole compounds
JP2010521515A5 (https=)
CZ301337B6 (cs) N-(Arylsulfonyl)-beta-aminokyselinový derivát a zpusob jeho prípravy
RU2007107164A (ru) 1а, 5а-тетрагидро-s-тиациклопропа[a]пенталены:трициклические производные тиофена в качестве агонистов рецепторов s1p1/edg1
RU97118779A (ru) Производные арилглицинамидов, способ их получения и фармацевтические композиции, содержащие эти соединения
CA2527159A1 (en) 3-aminomethyl-pyrrolidines as n-type calcium channel blockers
JP2005523310A5 (https=)
CA2407149A1 (en) Melanin-concentrating hormone antagonist
HUP0302966A2 (hu) Karboxamid-vegyületek és alkalmazásuk humán 11CBY receptor antagonistákként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EP0661266A1 (en) Substituted cyclic amine compounds as 5HT2 antagonists
RU2005111974A (ru) Производные пирролидона в качестве ингибиторов маов
JP2010504930A5 (https=)
JP2007532555A5 (https=)
JP2000504677A (ja) 5ht7レセプター・アンタゴニスト用のスルホンアミド誘導体
WO2004011430A1 (ja) ナトリウムチャネル阻害剤
RU2011127451A (ru) ПРОИЗВОДНЫЕ ТИЕНО[3,2-c]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ РАКА